Redbiotec today announced that it has closed an agreement with a listed, leading biopharmaceutical company in the field of prime-boost for cancer therapeutics to validate the approach. Christian Schaub, CEO of Redbiotec, states: “This is a major step for Redbiotec and a further proof of Redbiotec’s leadership in the development and production of complex VLPs.” Redbiotec develops VLPs for three main fields: 1) VLP vaccines, 2) VLPs for prime-boost / enhancement of cancer therapeutics and 3) VLPs, expressing GPCRs and ion channels, as targets for antibody screening.
